A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

Study Overview
=================
Brief Summary
-----------------
There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.

Detailed Description
-----------------
Knee osteoarthritis (KOA) is one of the leading causes of chronic pain and disability worldwide, affecting over 30% of older adults. It represents a major global health and economic burden to individuals and society. The rates of KOA have more than doubled in the past 70 years and continue to grow sharply, given increases in life expectancy and population body mass index (BMI). Surgery is often employed to treat KOA, but it is associated with a high rate of persistent pain, and is not a permanent solution. Numerous nonsurgical therapies have been advocated to treat pain in patients with KOA yet are not often used in clinical care. The limited pain relief and functional improvement seen in a subset of knee OA sufferers has led to a high rate of opioid use and disability in this population. The overarching goal of this study is to conduct a sequential parallel group randomized controlled trial (RCT) to evaluate the comparative effectiveness of conservative behavioral and non-opioid pharmacological treatments (Phase 1) and, among those that indicate interest in obtaining further treatment and those not eligible for conservative treatment, the benefits of procedural interventions (Phase 2). This study will also evaluate whether clinical and psychosocial phenotypes predict short- and longer-term treatment response. The results of this study will examine the effectiveness of each tested intervention and provide meaningful information regarding effectiveness across key subgroups of participants.

Official Title
-----------------
A Sequenced Strategy for Improving Outcomes in People With Knee Osteoarthritis Pain

Conditions
-----------------
Knee Osteoarthrosis

Intervention / Treatment
-----------------
* Drug: Duloxetine
* Combination Product: Intra-Articular Injection
* Procedure: Nerve Procedure with long acting blocks
* Procedure: Nerve Procedure with nerve ablation
* Behavioral: Pain Coping Skills Training
* Other: Best Practices


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Meets American College of Rheumatology Classification criteria for knee osteoarthritis Exclusion Criteria: Any inability to complete study procedures, including, but not limited to inadequate resources to mitigate low English language literacy Unstable medical condition that presents as an absolute or relative contraindication for participation (e.g., unstable angina, poorly controlled diabetes mellitus, end stage renal failure, automated implantable cardioverter-defibrillator that cannot be disabled before RFA). Severe untreated bleeding disorder (anticoagulants may be continued during phase II treatments in most patients) Severe vision or hearing impairment or serious cognitive impairment that could interfere with consent or outcome assessment Poorly controlled serious psychiatric condition Active substance abuse Scheduled joint replacement on the affected knee History of unilateral total knee arthroplasty (TKA) with complaints of KOA pain limited to the operated knee Ulcers or an open wound in the region of the index knee

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Interventional Model Description: Using a stepped care model, Phase 1 participants will be randomly assigned to minimally invasive treatments, including best practices, best practices plus duloxetine, and best practices plus duloxetine combined with a web-based pain coping skills training program. Those who note interest in additional treatment following completion of Phase 1, as well as those that are not eligible for Phase 1 treatment, will be randomly assigned to more aggressive procedures: intra-articular hyaluronic acid, steroid and local anesthetic injection, or a nerve procedure that would either include a long acting block or nerve ablation.
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Phase 1: Best Practices<br>Participants will receive an intervention from the best practices. | Other: Best Practices<br>* Best Practice includes treatments that experts recommend for knee arthritis pain. Best Practice can include topical or oral pain relievers, a structured exercise program, and weight management if BMI is over 30. Other non-invasive treatments such as acupuncture and yoga are also included.<br>|
| Active Comparator: Phase 1: Best Practices + Duloxetine<br>Participants will receive Duloxetine in addition to an intervention from the best practices. | Drug: Duloxetine<br>* Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.<br>* Other names: Cymbalta;Other: Best Practices<br>* Best Practice includes treatments that experts recommend for knee arthritis pain. Best Practice can include topical or oral pain relievers, a structured exercise program, and weight management if BMI is over 30. Other non-invasive treatments such as acupuncture and yoga are also included.<br>|
| Active Comparator: Phase 1:Best Practices + Duloxetine + Pain coping skills<br>Participants will receive Duloxetine and pain coping skills training in addition to an intervention from the best practices. | Drug: Duloxetine<br>* Duloxetine is a drug that is used to improve pain and function in people with knee osteoarthritis (KOA). Duloxetine is approved by the Food and Drug Administration (FDA) for the treatment of depression, anxiety disorder, fibromyalgia, and joint pain. It will be titrated up from 20 or 30mg according to a schedule provided by a study provider.<br>* Other names: Cymbalta;Behavioral: Pain Coping Skills Training<br>* Participants will be provided with a written manual that includes login information for the pain coping skills training website. They will be expected to log into the system weekly, work through the modules, and participate in skills practice. This intervention will be conducted in combination with best practices and duloxetine.<br>Other: Best Practices<br>* Best Practice includes treatments that experts recommend for knee arthritis pain. Best Practice can include topical or oral pain relievers, a structured exercise program, and weight management if BMI is over 30. Other non-invasive treatments such as acupuncture and yoga are also included.<br>|
| Active Comparator: Phase 2: Intra-Articular Injection (HA+)<br>Participants will receive an intra-articular injection of hyaluronic acid mixed with steroid and bupivacaine. | Combination Product: Intra-Articular Injection<br>* Intra-Articular Injection is an injection of 3-6 milliliter (mL) hyaluronic acid (HA) mixed with 1mL depo methylprednisolone (a steroid) and 2mL 0.5% bupivacaine (an anesthetic) into the knee.<br>|
| Active Comparator: Phase 2: Nerve Procedure: Long Acting Blocks<br>Participants will receive a nerve blocking procedure, long-acting local anesthetic, and steroid injection. | Procedure: Nerve Procedure with long acting blocks<br>* People assigned to receive this will have 1mL of a long-acting local anesthetic (a.k.a. liposomal bupivacaine or EXPAREL) and steroid injected into the knee.<br>|
| Active Comparator: Phase 2: Nerve Procedure: Nerve Ablation<br>Participants will receive a nerve ablation procedure and steroid injection. | Procedure: Nerve Procedure with nerve ablation<br>* People assigned to receive this will have heat applied to destroy the nerve signaling pain in the knee. Steroid will be administered after the procedure to reduce the risk of neuritis.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Pain Intensity as assessed by the Modified 4-item BPI Pain Scale | The Modified 4-item BPI Pain scale consists of 3 items from BPI Pain Intensity and 1 item from BPI Pain Interference. This is a continuous measure that will be calculated as the average of worst, average, current knee pain, and pain upon walking. | Baseline and 8 weeks post-treatment for Phase 1; Baseline and 12 weeks post-treatment for Phase 2 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Pain Interference as assessed by the BPI | The BPI Pain Interference domain assesses self-reported consequences of pain on relevant aspects of one's life. The BPI measures how much pain has interfered with seven daily activities, including general activity, walking, work, mood, enjoyment of life, relations with others, and sleep. BPI pain interference is typically scored as the mean of the seven interference items. BPI Interference ranges from 0-10 with higher scores reflecting greater pain interference in activities of daily living. | Baseline and 8 weeks post-treatment for Phase 1; Baseline and 12 weeks post-treatment for Phase 2 | 
| Change in Physical Functioning as assessed by the Knee Injury and Osteoarthritis Outcome Score (KOOS) | The KOOS evaluates function for participants with osteoarthritis of the knee that is related to injury and degeneration. The KOOS short form includes 12 items and measures pain, functional limitation and quality of life. Physical functioning questions cover everyday activities such as rising from sitting, standing getting in and out of the car and twisting/pivoting on the knee. Scores range from 0-100 with lower scores indicating worse knee symptoms. | Baseline and 8 weeks post-treatment for Phase 1; Baseline and 12 weeks post-treatment for Phase 2 | 
| Patient Global impression of Change (PGIC) | The PGIC scale evaluates all aspects of participants' health and assesses if there has been an improvement or decline in clinical status. It is a 7-item scale that ranges between a great deal worse to a great deal better. Higher scores reflect greater improvement in clinical status. | At 8 weeks post-treatment for Phase 1; At 12 weeks post-treatment for Phase 2 |